Recent Advances in Anti-Obesity Agents.
10.3904/kjm.2018.93.6.501
- Author:
Min Kyung KIM
1
;
Chul Sik KIM
Author Information
1. Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangdong Sacred Heart Hospital, Seoul, Korea.
- Publication Type:Review
- Keywords:
Obesity;
Anti-obesity agents
- MeSH:
Anti-Obesity Agents*;
Cardiovascular Diseases;
Chronic Disease;
Humans;
Life Style;
Liraglutide;
Obesity;
Risk Factors;
United States Food and Drug Administration
- From:Korean Journal of Medicine
2018;93(6):501-508
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Obesity is a chronic disorder that is a significant risk factor for diabetes, cardiovascular diseases, malignancy, and other chronic diseases. Lifestyle modifications form the basis of most treatments for obesity, but it has become clear that such modifications alone are not enough for many obese patients. When a behavioral approach is insufficient, pharmacological treatment may be recommended. In recent years, the US Food and Drug Administration (FDA) has withdrawn several therapeutic options for obesity due to their side effects, but has approved four novel anti-obesity agents. Until recently, orlistat was the only drug approved for the management of long-term obesity, but the US FDA approved the novel anti-obesity drugs lorcaserin and phentermine/topiramate in 2012, and naltrexone/bupropion and liraglutide in 2014. The present review discusses the different pharmacotherapeutic options for the treatment of obesity.
